Nitin P Kalia
Overview
Explore the profile of Nitin P Kalia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
235
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bakchi B, Maddipatla S, Gupta K, Singampalli A, Saxena D, Maitra R, et al.
Arch Pharm (Weinheim)
. 2024 Aug;
357(11):e2400358.
PMID: 39102220
The escalating severity of the menace posed by bacterial resistance has rendered the existing antibiotics less effective, thus necessitating the discovery of new antibacterial agents. The current study reports the...
2.
Hopfner S, Lee B, Kalia N, Miller M, Pethe K, Moraski G
Appl Sci (Basel)
. 2023 Jan;
11(19).
PMID: 36698770
The development of cytochrome oxidase (cyt-) inhibitors are needed for comprehensive termination of energy production in (Mtb) to treat tuberculosis infections. Herein, we report on the structure-activity-relationships (SAR) of 22...
3.
Hopfner S, Lee B, Kalia N, Miller M, Pethe K, Moraski G
RSC Med Chem
. 2021 May;
12(1):73-77.
PMID: 34046599
Cytochrome oxidase (Cyt-) is an attractive drug target in , especially in the context of developing a drug combination targeting energy metabolism. However, currently few synthetically assessable scaffolds target Cyt-....
4.
Lee B, Hards K, Engelhart C, Hasenoehrl E, Kalia N, Mackenzie J, et al.
EMBO Mol Med
. 2020 Dec;
13(1):e13207.
PMID: 33283973
The approval of bedaquiline has placed energy metabolism in the limelight as an attractive target space for tuberculosis antibiotic development. While bedaquiline inhibits the mycobacterial F F ATP synthase, small...
5.
Kalia N, Lee B, Ab Rahman N, Moraski G, Miller M, Pethe K
Sci Rep
. 2019 Jun;
9(1):8608.
PMID: 31197236
The influence of carbon metabolism on oxidative phosphorylation is poorly understood in mycobacteria. M. tuberculosis expresses two respiratory terminal oxidases, the cytochrome bc:aa and the cytochrome bd oxidase, which are...
6.
Lee B, Kalia N, Jin X, Hasenoehrl E, Berney M, Pethe K
J Biol Chem
. 2018 Dec;
294(6):1936-1943.
PMID: 30530783
Energy metabolism has recently gained interest as a target space for antibiotic drug development in mycobacteria. Of particular importance is bedaquiline (Sirturo), which kills mycobacteria by inhibiting the FF ATP...
7.
Bouvier G, Simenel C, Jang J, Kalia N, Choi I, Nilges M, et al.
Biochemistry
. 2018 Dec;
58(6):526-533.
PMID: 30521325
Detailed information on hit-target interaction is very valuable for drug discovery efforts and indispensable for rational hit to lead optimization. We developed a new approach combining NMR in whole-cells in-cell...
8.
Singh S, Kalia N, Joshi P, Kumar A, Sharma P, Kumar A, et al.
Front Microbiol
. 2017 Oct;
8:1868.
PMID: 29046665
This study elucidated the role of boeravinone B, a NorA multidrug efflux pump inhibitor, in biofilm inhibition. The effects of boeravinone B plus ciprofloxacin, a NorA substrate, were evaluated in...
9.
Kalia N, Hasenoehrl E, Ab Rahman N, Koh V, Ang M, Sajorda D, et al.
Proc Natl Acad Sci U S A
. 2017 Jun;
114(28):7426-7431.
PMID: 28652330
The recent discovery of small molecules targeting the cytochrome : in triggered interest in the terminal respiratory oxidases for antituberculosis drug development. The mycobacterial cytochrome : consists of a menaquinone:cytochrome...
10.
Thota N, Reddy M, Kumar A, Khan I, Sangwan P, Kalia N, et al.
Eur J Med Chem
. 2010 Jul;
45(9):3607-16.
PMID: 20605275
A new series of 3-(substituted-3,4-dihydronaphthyl)-2-propenoic acid amides has been prepared through convergent synthetic strategies and tested in combination with ciprofloxacin against NorA overexpressing Staphylococcus aureus 1199B as test strain for...